Cefepime (BMY-28142) is a fourth-generation cephalosporin used to treat a wide range of Gram-positive and Gram-negative bacterial infections. It is approved for the management of pneumonia, urinary tract infections, skin and soft-tissue infections, intra-abdominal infections, and febrile neutropenia. Cefepime exerts its bactericidal effect by covalently binding and inhibiting penicillin-binding proteins (PBPs), thereby disrupting the final step of bacterial cell wall synthesis and leading to cell death.